151 related articles for article (PubMed ID: 30147719)
1. Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.
Neubauer K; Matusiewicz M; Bednarz-Misa I; Gorska S; Gamian A; Krzystek-Korpacka M
Gastroenterol Res Pract; 2018; 2018():7265812. PubMed ID: 30147719
[TBL] [Abstract][Full Text] [Related]
2. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
[TBL] [Abstract][Full Text] [Related]
3.
Loganes C; Valencic E; Pin A; Marini E; Martelossi S; Naviglio S; De Leo L; Not T; Monasta L; Tommasini A; Marcuzzi A
World J Gastroenterol; 2016 Nov; 22(44):9734-9743. PubMed ID: 27956797
[TBL] [Abstract][Full Text] [Related]
4. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Lymphocytes of Patients with Inflammatory Bowel Disease Have Altered Concentrations of Key Apoptosis Players: Preliminary Results.
Neubauer K; Woźniak-Stolarska B; Krzystek-Korpacka M
Biomed Res Int; 2018; 2018():4961753. PubMed ID: 30515402
[TBL] [Abstract][Full Text] [Related]
8. Peripheral cytokine profile in Chilean patients with Crohn's disease and ulcerative colitis.
Beltrán CJ; Candia E; Erranz B; Figueroa C; Gonzalez MJ; Quera R; Hermoso MA
Eur Cytokine Netw; 2009 Mar; 20(1):33-8. PubMed ID: 19318319
[TBL] [Abstract][Full Text] [Related]
9. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.
Macpherson A; Khoo UY; Forgacs I; Philpott-Howard J; Bjarnason I
Gut; 1996 Mar; 38(3):365-75. PubMed ID: 8675088
[TBL] [Abstract][Full Text] [Related]
10. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique.
Jeziorska M; Haboubi N; Schofield P; Woolley DE
J Pathol; 2001 Aug; 194(4):484-92. PubMed ID: 11523058
[TBL] [Abstract][Full Text] [Related]
11. Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease.
Gabriëls RY; Bourgonje AR; von Martels JZH; Blokzijl T; Weersma RK; Galinsky K; Juarez J; Faber KN; Kats-Ugurlu G; Dijkstra G
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887905
[TBL] [Abstract][Full Text] [Related]
12. Relationship between fecal lactoferrin and inflammatory bowel disease.
Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
[TBL] [Abstract][Full Text] [Related]
13. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity.
Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C
J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944
[TBL] [Abstract][Full Text] [Related]
14. Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement?
Koek GH; Verleden GM; Evenepoel P; Rutgeerts P
Respir Med; 2002 Jul; 96(7):530-5. PubMed ID: 12194639
[TBL] [Abstract][Full Text] [Related]
15. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease.
Nielsen OH; Rüdiger N; Gaustadnes M; Horn T
Scand J Gastroenterol; 1997 Oct; 32(10):1028-34. PubMed ID: 9361176
[TBL] [Abstract][Full Text] [Related]
16. Comparison of geographic distributions of Irritable Bowel Syndrome with Inflammatory Bowel Disease fail to support common evolutionary roots: Irritable Bowel Syndrome and Inflammatory Bowel Diseases are not related by evolution.
Szilagyi A; Xue X
Med Hypotheses; 2018 Jan; 110():31-37. PubMed ID: 29317064
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum eotaxin levels in patients with inflammatory bowel disease.
Mir A; Minguez M; Tatay J; Pascual I; Peña A; Sanchiz V; Almela P; Mora F; Benages A
Am J Gastroenterol; 2002 Jun; 97(6):1452-7. PubMed ID: 12094864
[TBL] [Abstract][Full Text] [Related]
18. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
19. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
[TBL] [Abstract][Full Text] [Related]
20. Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
Englund H; Lidén K K; Lind T; Sundström T; Karling P
Scand J Gastroenterol; 2017 Mar; 52(3):300-305. PubMed ID: 27832710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
